Intranasal Ketamine vs. Ketamine Infusions: A Comprehensive Comparison
- Dr. Peeva
- 2 days ago
- 4 min read
In recent years, ketamine has become a groundbreaking treatment option for various mental health conditions, including treatment-resistant depression, anxiety disorders, PTSD, chronic pain, and suicidal ideation. As its popularity grows, patients and providers alike are faced with an important question: What is the most effective route of administration?
While ketamine can be delivered in several ways, two of the most common methods used in clinical practice are intranasal ketamine and intravenous (IV) ketamine infusions. Understanding the differences between these two routes is crucial for informed decision-making, especially for individuals seeking fast, reliable, and medically validated results.
This article will explore the key differences between intranasal and infusion-based ketamine, with a focus on bioavailability, efficacy, safety, clinical outcomes, and scientific evidence. We will also explain why ketamine infusions remain the gold standard, supported by robust clinical protocols and decades of research.
1. What is Intranasal Ketamine?
Intranasal ketamine involves spraying a low dose of ketamine directly into the nasal passages. This method allows for absorption through the mucous membranes in the nose. One FDA-approved formulation of intranasal ketamine is Spravato (esketamine), which is derived from only one isomer (S-ketamine) and is used under supervision in certified clinics.
Although convenient and less invasive, intranasal administration has significant limitations in terms of bioavailability and efficacy. The body absorbs only a portion of the ketamine, and variability between patients is high.
2. What is IV Ketamine Infusion Therapy?
IV ketamine infusions involve administering a precisely controlled dose of ketamine
directly into the bloodstream. The process takes place in a clinical setting, usually over a 40- to 60-minute session, with careful medical supervision.
IV infusions deliver 100% bioavailability, meaning the entire dose reaches systemic circulation without metabolic degradation. Furthermore, IV ketamine delivers a racemic mixture, which includes both R- and S-ketamine isomers—both of which contribute to its therapeutic effect.
3. Bioavailability: IV Infusion vs. Intranasal
One of the most critical differences between IV and intranasal ketamine lies in bioavailability, or how much of the drug actually enters the bloodstream and becomes active in the body:
Route of Administration | Bioavailability |
IV Infusion | ~100% |
Intranasal | ~30-50% |
IV infusion provides consistent, predictable dosing with immediate effect. In contrast, intranasal absorption can vary significantly depending on nasal congestion, technique, and individual anatomy.
4. Importance of Both Ketamine Isomers
Ketamine exists as a racemic mixture containing two mirror-image molecules: R-ketamine and S-ketamine (also known as esketamine). While Spravato contains only the S-isomer, IV ketamine infusions provide both isomers, which is vital for achieving the full spectrum of therapeutic effects.
S-ketamine (esketamine): Has stronger NMDA receptor antagonism and is thought to be responsible for some of the rapid antidepressant effects.
R-ketamine: Emerging evidence suggests R-ketamine may provide longer-lasting and more robust antidepressant effects with fewer dissociative side effects.
Studies indicate that both isomers contribute to ketamine’s mechanism of action. The combined effect of the racemic mixture delivered via infusion is superior in many cases to single-isomer administration.
5. Clinical Outcomes and Speed of Response
IV ketamine infusions have consistently shown more rapid onset and more robust therapeutic effects than intranasal formulations. Clinical trials and real-world evidence support this difference:
Onset of Relief: IV ketamine can produce noticeable relief of depression or suicidal ideation within hours, sometimes after just one session. Intranasal ketamine typically takes longer and may require multiple sessions before a meaningful response is observed.
Efficacy Rates: Studies report response rates of 70–80% for treatment-resistant depression with IV ketamine, while intranasal formulations often have lower and more variable response rates.
Sustained Relief: IV ketamine infusions often produce longer-lasting effects, particularly when administered in a structured protocol involving multiple sessions over 2–3 weeks.
6. Evidence-Based Protocols: Infusions are the Gold Standard
The vast majority of peer-reviewed studies, clinical trials, and treatment protocols are based on ketamine infusions, not intranasal delivery. These protocols are the foundation of ketamine therapy in psychiatry and pain management.
Key studies that have shaped current clinical practices—including NIH-funded trials—have consistently used IV ketamine:
Berman et al. (2000): First study showing rapid antidepressant effects of IV ketamine.
Zarate et al. (2006): Demonstrated ketamine’s effectiveness in treatment-resistant depression.
Multiple studies in the 2010s refined infusion dosing schedules and response predictors.
These evidence-based protocols have led to structured treatment models now widely used in ketamine clinics across the country.
7. Safety and Supervision
Both intranasal and IV ketamine require medical supervision, but IV infusions are inherently safer when provided in a controlled clinical environment:
Monitoring: Patients undergoing IV infusions are continuously monitored for blood pressure, heart rate, oxygen saturation, and mental status.
Control: Clinicians can adjust dosing in real-time based on patient response.
Support: Any adverse effects or dissociative experiences can be managed immediately by trained professionals.
In contrast, while Spravato is administered under supervision, non-prescription or compounded intranasal ketamine (e.g., mail-order from telemedicine platforms) poses greater risks of misuse, inadequate dosing, and poor outcomes.
8. Cost Considerations
While IV infusions may have a higher upfront cost, they often yield better outcomes in fewer sessions. Intranasal ketamine may seem more convenient or less expensive per dose, but the need for repeated use and lower efficacy can make it less cost-effective over time.
Moreover, because infusion therapy is protocol-driven and based on reliable clinical outcomes, patients are more likely to achieve remission and reduce overall long-term treatment expenses.
9. Patient Suitability
IV ketamine infusions are particularly beneficial for:
Patients with severe or treatment-resistant depression
Individuals with high suicide risk needing rapid intervention
Those who have failed other pharmacologic treatments
Intranasal ketamine may be considered for maintenance after initial infusion therapy or for patients with mild to moderate symptoms who prefer a less invasive option—but always under the guidance of a qualified medical provider.
10. Final Thoughts: Why Infusions Lead the Field
Despite the growing availability of ketamine in various forms, IV infusion therapy remains the gold standard. This method provides full bioavailability, delivers both R- and S-isomers, and is backed by the strongest clinical evidence.
In the world of psychiatric and chronic pain treatment, outcomes matter—and IV ketamine infusions produce faster, more robust, and longer-lasting results. Most importantly, they are the foundation upon which all treatment protocols are built.
For patients seeking real change—not just convenience—IV ketamine administered by experienced professionals offers the highest standard of care available today.
Ready to explore ketamine infusion therapy?
At Propel Therapeutics, we offer safe, effective, and research-driven ketamine infusion treatments for depression, anxiety, PTSD, and chronic pain. Our expert team ensures each session is tailored to your needs—with safety, science, and compassion at the forefront.
Comments